Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kyndryl Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.14 (market cap $29.60B), while Kyndryl Holdings Inc trades at $12.78 (market cap $2.91B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.2× Kyndryl Holdings Inc's market cap. Which is the better fit depends on your goals.
| ALNY | KD | |
|---|---|---|
Market Cap | $29.60B | $2.91B |
Sector | Health | Technology |
52-Week High | $491.22 | $33.14 |
52-Week Low | $205.48 | $10.59 |
Enterprise Value | $27.56B | $5.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Kyndryl (KD) trades at $13.63, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company shows improving profitability with 2025 net income of $252M after years of losses, though recent Q1 2027 earnings missed expectations. The acquisition of Healthcare IT Leaders and new AI services demonstrate strategic growth initiatives.
While analyst consensus leans Hold (71%) with a $13.50 price target near current levels, improving cash flow and debt management provide stability. Key risks include revenue declines, ongoing investigations, and competitive pressures in IT services. The stock presents a turnaround story with moderate upside potential balanced by execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
